4-chloro-6-cyano-7-(3-methylsulphonylpropoxy)quinoline | 398487-57-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-chloro-6-cyano-7-(3-methylsulphonylpropoxy)quinoline
• 英文别名: 4-chloro-7-(3-methylsulfonylpropoxy)quinoline-6-carbonitrile
• CAS: 398487-57-5
• 化学式: C₁₄H₁₃ClN₂O₃S
• 分子量: 324.788
• InChiKey: CORPADBMZLBDRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  88.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氟-5-羟基-2-甲基吲哚 、 4-chloro-6-cyano-7-(3-methylsulphonylpropoxy)quinoline 以to give 6-cyano-4-(4-fluoro-2-methylindol-5-yloxy)-7-(3-methylsulphonylpropoxy)quinoline的产率得到6-cyano-4-(4-fluoro-2-methylindol-5-yloxy)-7-(3-methylsulphonylpropoxy)quinoline
  参考文献：
  名称：

  Quinoline derivatives having vegf inhibiting activity

  摘要：

  本发明涉及式(I)的化合物，其中：G1、G2、G3、G4和G5中的任意一个是氮，其他四个是-CH-，或者G1、G2、G3、G4和G5都是-CH-; Z是-O-、-NH-、-S-、-CH2-或直接键；Z与G1、G2、G3和G4中的任意一个相连；n是0到5的整数；m是0到3的整数；R a代表氢或氟；R b、R1和R2在此被定义并且它们的盐，制备这些化合物的方法，包含式I的化合物或其药学上可接受的盐作为活性成分的制药组合物以及在制造用于在温血动物中产生抗血管生成和/或血管通透性降低作用的药物时使用式I的化合物。式(I)的化合物和其药学上可接受的盐抑制VEGF的作用，在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值。

  公开号：

  US20030199491A1
• 作为产物：
  描述：

  4-chloro-7-hydroxyquinoline-6-carbonitrile 、 3-甲砜基-1-丙醇 在 crude product 作用下， 以to give 4-chloro-6-cyano-7-(3-methylsulphonylpropoxy)quinoline (428 mg, 90%)的产率得到4-chloro-6-cyano-7-(3-methylsulphonylpropoxy)quinoline
  参考文献：
  名称：

  Quinoline derivatives having VEGF inhibiting activity

  摘要：

  本发明涉及式(I)的化合物，其中：G1、G2、G3、G4和G5中任意一个是氮，其余四个是—CH—，或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、—NH—、—S—、—CH2—或直接键；Z与G1、G2、G3和G4中的任意一个相连；n是0到5的整数；m是0到3的整数；Ra代表氢或氟；Rb、R1和R2如本文所定义；以及该类化合物的盐、制备该类化合物的方法、包含式(I)的化合物或其药学上可接受的盐作为活性成分的制药组合物以及在制造用于在恒温动物中产生抗血管生成和/或血管通透性降低效应的药物的过程中使用式(I)的化合物。式(I)的化合物及其药学上可接受的盐抑制VEGF的作用，在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值的性质。

  公开号：

  US07371765B2

文献信息

• Quinoline derivatives having vegf inhibiting activity
  申请人：——

  公开号：US20030199491A1

  公开（公告）日：2003-10-23

  The invention relates to compounds of formula (I) wherein: either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—, or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, —NH—, —S—, —CH 2 — or a direct bond; Z is linked to any one of G 1 , G 2 , G 3 and G 4 ; n is an integer from 0 to 5; m is an integer from 0 to 3; R a represents hydrogen or fluoro; R b , R 1 and R 2 are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blodded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.

  该发明涉及以下式（I）的化合物：其中：G1、G2、G3、G4和G5中的任意一个是氮，其他四个是—CH—，或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、—NH—、—S—、—CH2—或直接键；Z与G1、G2、G3和G4中的任意一个相连；n是从0到5的整数；m是从0到3的整数；R代表氢或氟；Rb、R1和R2在此处定义，并且其盐，制备这种化合物的方法，含有式I的化合物或其药学上可接受的盐作为活性成分的药物组合物，以及利用式I的化合物制造用于在温血动物中产生抗血管生成和/或血管通透性降低作用的药物的用途。式I的化合物及其药学上可接受的盐抑制VEGF的作用，这是治疗多种疾病状态的有价值的特性，包括癌症和类风湿性关节炎。
• Quinoline derivatives having VEGF inhibiting activity
  申请人：AstraZeneca AB

  公开号：US07371765B2

  公开（公告）日：2008-05-13

  The invention relates to compounds of formula (I) wherein: either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or a direct bond; Z is linked to any one of G1, G2, G3 and G4; n is an integer from 0 to 5; m is an integer from 0 to 3; Ra represents hydrogen or fluoro; Rb, R1 and R2 are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.

  本发明涉及式(I)的化合物，其中：G1、G2、G3、G4和G5中任意一个是氮，其余四个是—CH—，或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、—NH—、—S—、—CH2—或直接键；Z与G1、G2、G3和G4中的任意一个相连；n是0到5的整数；m是0到3的整数；Ra代表氢或氟；Rb、R1和R2如本文所定义；以及该类化合物的盐、制备该类化合物的方法、包含式(I)的化合物或其药学上可接受的盐作为活性成分的制药组合物以及在制造用于在恒温动物中产生抗血管生成和/或血管通透性降低效应的药物的过程中使用式(I)的化合物。式(I)的化合物及其药学上可接受的盐抑制VEGF的作用，在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值的性质。
• QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP1313726A1

  公开（公告）日：2003-05-28
• US7371765B2
  申请人：——

  公开号：US7371765B2

  公开（公告）日：2008-05-13
• [EN] QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY<br/>[FR] DERIVES DE LA QUINOLINE PRESENTANT UNE ACTIVITE INHIBANT LE FACTEUR DE CROISSANCE VEGF
  申请人：ASTRAZENECA AB

  公开号：WO2002012226A1

  公开（公告）日：2002-02-14

  The invention relates to compounds of formula (I) wherein: either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are -CH-, or G1, G2, G3, G4 and G5 are all -CH-; Z is -O-, -NH-, -S-, -CH2- or a direct bond; Z is linked to any one of G1, G2, G3 and G4; n is an integer from 0 to 5; m is an integer from 0 to 3; Ra represents hydrogen or fluoro; R?b, R1 and R2¿ are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blodded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.